Eli Lilly's stock has been under pressure due to recent headwinds, but the company's weight loss drugs are gaining market share, which is a positive sign. Additionally, potential policy changes under the Biden administration could benefit the company, although these changes may not be resolved before Trump takes office. This combination of factors suggests a positive short-term outlook for the stock.